Click here to go to the previous page
Towards an Effective Virtual R&D Team for Faster Accessing of the East Asian Market
Program Code:
344
Date:
Wednesday, June 26, 2013
Time:
1:45 PM to 3:15 PM
EST
CHAIR
:
Deborah Chee,
MD,PhD,MBA (SCHNON), Medical Director,
AbbVie Korea Ltd., Republic of Korea
Deborah Chee is currently Medical Director of AbbVie Korea, R&D Committee chair of Korean Research-based Pharmaceutical Industry Association and VP of Korean Society of Clinical Pharmacoloy. She has extensive experience in development and implementation of Korea and Asia development starategies,
|
SPEAKER
(S):
President & CEO, IDEC Inc. since 2003 Head of R&D Japan at Pharmacia (1997-03) and Schering AG (1989-97) Asst. Prof. Internal Medicine at Fujita Gakuen and Keio University, Tokyo, Japan 1985-89 Clinical training in Internal Medicine Essen University, Germany Licenced physician in Germany & Japan
|
Howard Lee, MD,PhD (SPKSUP), Professor, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Republic of Korea
Philip Bonasia,
PhD (SPKNON), Executive Director and Head, Chemistry and Pharmaceutical Sciences,
Sunovion Pharmaceuticals Inc., United States
Phil earned his Ph.D. at UC Berkeley and worked at Merck from 1993-2000. In 2000 he moved to Sepracor in Marlborough, MA. In 2009, Sepracor was aquired by Dainippon Sumitomo and became Sunovion Pharmaceuticals. Phil ran the Analytical R&D group for 12 years and is now Head of the CPS department.
|
Description
Strategic use of a "virtual" R&D team model could benefit companies that have limited capabilities in East Asian markets - including Japan, China, Korea and Taiwan - to minimize the drug lag and to maximize product value in these markets.